Logo

Eli Lilly and AbCellera's Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Receive the US FDA's EUA for COVID-19

Share this

Eli Lilly and AbCellera's Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Receive the US FDA's EUA for COVID-19

Shots:

  • The FDA authorized EUA for bamlanivimab (700 mg) and etesevimab (1400 mg) for the treatment of mild to mod. COVID-19 patients aged ≥12yrs. who are at high risk for progressing to severe COVID-19 and/or hospitalization
  • The EUA is based on P-III BLAZE-1 trial in ≥1-000 COVID-19 patients showed 70% reduction in hospitalizations. Lilly plans to manufacture 250-000+ doses in Q1’ 21 and up to 1M doses by mid-2021
  • The FDA authorizes new protocols for infusion of bamlanivimab as monothx. and bamlanivimab and etesevimab together in as few as 16 and 21 min respectively

 ­ Ref: Businesswire | Image: Eli Lilly

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions